What is claimed is:

1. A composition comprising:

a GLP-1-Fc-FGF21 fusion protein and a buffer.

2. The composition according to claim 1, wherein the GLP-1-Fc-FGF21 fusion protein comprises an amino acid sequence as shown in any one of SEQ ID NO: 1-12.

3. The composition according to claim 1 or claim 2, wherein the concentration of the GLP-1-Fc-FGF21 fusion protein in the composition is:

(i) 1-100 mg/mL;

(ii) 2-80 mg/mL;

(iii) 5-70 mg/mL;

(iv) 2-55 mg/mL;

(v) 10-65 mg/mL; or

(vi) 20~60 mg/mL.

4. The composition according to claim 3, wherein the pH value of the composition is 6.2-8.0 or 6.4-8.0.

5. The composition according to any one of claims 1 to 4, wherein the buffer comprises at least one of:

(i) a histidine buffer;

(ii) a citrate buffer;

(iii) a phosphate buffer, or

(iv) a Tris buffer.

6. The composition according to claim 5, wherein the concentration of the buffer in the composition is:

(i) 5-30 mM;

(ii) 5-25 mM;

(iii) 8-25 mM;

(iv) 5-20 mM;

(v) 8-12 mM; or

(vi) 10-20 mM.

7. The composition according to claim 1, wherein the composition further comprises at least one of:

(i) an osmotic pressure regulator, optionally comprising at least one of mannitol, sucrose, trehalose, and sodium chloride, and optionally having a concentration in the composition of 30-100 mg/mL or 1-10 mg/mL;

(ii) a surfactant, optionally comprising at least one of polysorbate 80, polysorbate 20, and poloxamer 188, and optionally having a concentration in the composition of 0.1-10 mg/mL, 0.1-1.5 mg/mL or 0.1~0.7 mg/mL;

(iii) a preservative, optionally comprising at least one of phenol and m-cresol, and optionally having a concentration in the composition of 0.1-10 mg/mL or 1.0-5.0 mg/mL; and

(iv) a metal chelating agent, optionally comprising at least one of disodium edetate and calcium disodium edetate, and optionally having a concentration in the composition of 0.01-1 mg/mL or 0.05-0.5 mg/mL.

8. The composition according to any one of claims 1 to 6, wherein the buffer is a histidine buffer, and the concentration of the GLP-1-Fc-FGF21 fusion protein in the composition is 25-100 mg/mL, or 25-55 mg/mL;

optionally, wherein:

(i) the concentration of the histidine buffer in the composition is 5-30 mM, 8-20 mM, or 8-12 mM;

(ii) the pH of the composition is 6.7-7.5, preferably 6.9-7.5;

(iii) the osmotic pressure regulator is mannitol, and the concentration of the osmotic pressure regulator in the composition is 30-50 mg/mL; the osmotic pressure regulator is sucrose, and the concentration of the osmotic pressure regulator in the composition is 60-100 mg/mL, preferably 80-100 mg/mL; or the osmotic pressure regulator is trehalose, and the concentration of the osmotic pressure regulator in the composition is 40-100 mg/mL, preferably 50-70 mg/mL; and/or

(iv) the surfactant is polysorbate 80, and the concentration of the surfactant in the

composition is 0.1-2 mg/mL, preferably 0.4~1.3 mg/mL; or the surfactant is polysorbate 20, and the concentration of the surfactant in the composition is 0.1-1.5 mg/mL, preferably 0.1-0.5 mg/mL.

9. The composition according to any one of claims 1 to 8, wherein the dosage form of the composition is a liquid formulation, preferably an injection.

10. An injection comprising:

(i) a GLP-1-Fc-FGF21 fusion protein,

(ii) a histidine buffer,

(iii) mannitol,

(iv) polysorbate 80 or polysorbate 20; and

(v) optionally disodium edetate or calcium disodium edetate,

wherein the GLP-1-Fc-FGF21 fusion protein comprises an amino acid sequence as shown in any one of SEQ ID NO: 1-12, and the concentration of the GLP-1-Fc-FGF21 fusion protein in the injection is 25-100 mg/mL, 25-95 mg/mL, 25-90 mg/mL, 25-85 mg/mL, 25-80 mg/mL, 25-75 mg/mL, 25-70 mg/mL, 25-65 mg/mL, 25-60 mg/mL, 25-55 mg/mL, or 25-50 mg/mL;

wherein the concentration of the histidine buffer in the injection is 8-25 mM, preferably 10-20 mM;

wherein the concentration of mannitol in the injection is 35-45 mg/mL;

wherein the concentration of polysorbate 80 in the injection is 0.4-1.5 mg/mL or 0.4-1.3 mg/mL, or the concentration of polysorbate 20 in the injection is 0.1-0.5 mg/mL;

wherein if present the concentration of the metal chelating agent in the injection is 0.05-0.5 mg/mL;

wherein the pH of the injection is 6.9-7.5;

preferably, wherein the injection does not contain disodium edetate or calcium disodium edetate.

11. An injection comprising:

a GLP-1-Fc-FGF21 fusion protein, a histidine buffer, mannitol, polysorbate 80, and optionally disodium edetate or calcium disodium edetate;

wherein the GLP-1-Fc-FGF21 fusion protein comprises an amino acid sequence as shown in any one of SEQ ID NO: 1-12, and the concentration of the GLP-1-Fc-FGF21 fusion protein in the injection is 3-25 mg/mL;

wherein the concentration of the histidine buffer in the injection is 5-30 mM, preferably 10-20 mM;

wherein the concentration of mannitol in the injection is 40-50 mg/mL;

wherein the concentration of polysorbate 80 in the injection is 0.1-1.5 mg/mL;

wherein if present the concentration of the metal chelating agent in the injection is 0.05-0.5 mg/mL;

wherein the pH of the injection is 6.4-8.0;

preferably, wherein the injection does not contain disodium edetate or calcium disodium edetate.

12. The injection according to claim 10 or claim 11, further comprising a preservative.

13. The injection according to claim 12, wherein the preservative is at least one selected from phenol, m-cresol, benzyl alcohol, and phenoxyethanol;

optionally, wherein:

(i) the concentration of phenol in the composition or injection is 0-7 mg/mL, preferably 3-7 mg/mL; and/or

(ii) the concentration of m-cresol in the composition or injection is 0-4 mg/mL, preferably 2-4 mg/mL.

14. Use of the composition according to any one of claims 1 to 9 or the injection according to any one of claims 10 to 13 for the manufacture of a medicament for treating or preventing a metabolic disease;

optionally, wherein the metabolic disease is selected from diabetes, hyperlipidemic obesity, and diseases associated with fatty liver;

optionally, wherein the diseases associated with fatty liver include non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibrosis, and cirrhosis.

15. An injection device or container comprising:

the composition according to any one of claims 1 to 9 or the injection according to any one of claims 10 to 13;

optionally, wherein the injection device or container comprises at least one selected from bottle, a vial, a cartridge, and a syringe;

preferably, wherein the syringe comprises at least one selected from an auto-injector and a prefilled syringe.